Medindia

X

MAQUET Cardiovascular Announces Dedication of Its New United States Headquarters in Wayne, NJ

Wednesday, October 14, 2009 General News J E 4
Advertisement
Relocation of manufacturing of cardiovascular medical devices from Puerto Rico to New Jersey creates 350 new jobs

WAYNE, N.J., Oct. 14 -- MAQUET Cardiovascular LLC, a leading, global provider of cardiovascular technologies, today celebrated and formally opened its new United States headquarters in Wayne, New Jersey. The dedication ceremony was attended by local and state dignitaries, the MAQUET leadership team, and local employees from the company’s cardiovascular, critical care and surgical workplace divisions.

“MAQUET Cardiovascular has deep ties to the state of New Jersey, and it is with great honor and pride that we dedicate our new facility today,” said Christian Keller, President and CEO, MAQUET Cardiovascular. “From our new U.S. headquarters and through the dedication of our employees around the globe, we plan to exceed in our commitment to deliver technology and products that improve the clinical and economic outcomes for high acuity cardiac patients.”

MAQUET Cardiovascular’s history has its roots in the historic Paterson textile manufacturing industry that flourished in New Jersey in the 19th and 20th centuries. While much of this industry has disappeared in the state, MAQUET Cardiovascular employs many descendants of the past textile industry who apply this same skilled trade and craftsmanship to the production of its knitted and woven vascular grafts, used across the U.S. in life-saving procedures every day.

MAQUET Cardiovascular’s history in New Jersey started with Meadox Medical, which was founded in Haledon in 1954. Meadox was acquired by Boston Scientific Corporation in 1995. In 2008, MAQUET acquired the Meadox business and the former Guidant cardiovascular surgery business from Boston Scientific, and formed MAQUET Cardiovascular. In 2009, the company acquired Datascope, another New Jersey- based medical device company, and emerged as a leading global provider of the top-selling cardiac and vascular surgery products on the market today.

“MAQUET would like to thank the New Jersey Economic Development Authority for its support of our growth efforts,” said William Friedberg, President of MAQUET Cardiovascular’s Vascular Interventions business unit. “The cooperative nature of the state government, favorable economic incentives, and the skilled workforce of the surrounding areas made Wayne, New Jersey, the perfect community in which to develop our world-class facilities and headquarters.”

With the unemployment rate in New Jersey at 9.5 percent, MAQUET Cardiovascular’s continued expansion and ramp-up of its wholly-owned manufacturing facility will hire up to 350 new employees while maintaining jobs for 1,100 statewide residents as it seeks to ramp up its wholly-owned manufacturing activities that were previously conducted primarily in Puerto Rico. The company hopes to expand its New Jersey work force in the future but, like many medical device companies, is concerned about potential new taxes that would inhibit growth in the medical technology sector. The company has already invested nearly $40 million to develop its new headquarters and manufacturing areas. The 282,000 square foot site will include state-of-the-art manufacturing and house a Surgical Academy and Showroom, complete with full-scale operating room environments for training and education. Construction is also slated to start soon on an auditorium that will seat 180 people with state-of-the-art multimedia capabilities, including interpreting and production booths.

About MAQUET Cardiovascular

MAQUET Cardiovascular was formed in 2003 when MAQUET combined its existing Cardiopulmonary business with Jostra’s equipment and consumables for open heart surgery and Siemens Life Support Systems that GETINGE acquired in 2003. In 2008, it added the Cardiac Surgery and Vascular Interventions businesses that GETINGE acquired from Boston Scientific and Guidant in 2008. In 2009, it added the cardiac assist businesses that GETINGE acquired from Datascope. Today, MAQUET Cardiovascular is recognized as a diversified cardiovascular medical device company that develops, manufactures and markets leading brands in interventional cardiology, cardiovascular and vascular surgery and critical care.

About The MAQUET Group

The MAQUET Group is the global market leader for Medical Systems, focusing on the Operating Room (OR) and Intensive Care Unit (ICU). The integrated products of MAQUET are specially designed to deliver optimal clinical treatment and therapy concepts within acute care hospitals. MAQUET provides innovative medical solutions from three divisions:

  • Cardiovascular with products for cardiac assist (intra-aortic balloon counterpulsation therapy), coronary artery bypass surgery, heart valve repair, aneurysm and vascular repair, peripheral interventions and extracorporeal circulation
  • Critical Care for intensive care ventilators and anesthesia machines
  • Surgical Workplaces for OR tables, lights and ceiling service units, prefabricated OR and ICU suites as well as telemedicine for the OR integration.

MAQUET is a subsidiary of the publicly-listed Swedish group of companies GETINGE AB, a company with over $2.8 billion in revenues (2008 fiscal year) and 12,800 employees worldwide. In 2008 MAQUET itself generated pro-forma revenues (including the acquisition of Datascope Corp.) of over $1.4 billion. The company now has 5,000 employees in 34 international sales and service organizations, as well as a network of more than 200 sales representatives.

www.maquet.com

www.getinge.com

MAQUET – The Gold Standard.

SOURCE MAQUET Cardiovascular LLC

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Cardiva Medical, Inc. Announces the Departure of i...
S
AcelRx Pharmaceuticals Hires Nigel Ray as Vice Pre...